Netherlands· NL-267c892bcce2

Pahrilan 0,5 mg filmomhulde tabletten

A riociguat product containing riociguat, registered in Netherlands by G.L. Pharma GmbH. The same ATC class is registered in 17 of our 19 countries.

ATC C02KX05

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about riociguatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Riociguat is registered in 17 of 19 countries.

Countries holding a registration under ATC C02KX05 (riociguat), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
10 of them publish a price we can compare per daily dose

Search riociguat products by name

Riociguat · ATC C02KX05

17 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Ireland
Italyprice
Japan
Netherlands
Norwayprice
Polandprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of riociguat costs, country by country.

Normalised to the WHO defined daily dose (4.5 mg), the median price runs from $0.056 in France to $219.06 in Switzerland — a ×3926 gap.

3 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Riociguat · price per daily dose (4.5 mg)

USD · FX 28 Sept 2026

CH Switzerland$219.06
IT Italy$147.94
FR France$0.056

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: RIOCIGUAT
Manufacturer: G.L. Pharma GmbH
Country: Netherlands (NL)
ATC code: C02KX05
ATC class: Riociguat
Defined daily dose: 4.5 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
134321

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

140 interactions on record for riociguat.

Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check riociguat against other medicines How interaction checks work

Riociguat · interactions on record

140 records

10 severe
103 moderate

Most severe, free to view

DipyridamoleB01AC07severe
DipyridamolC01DX29severe
TheophyllinC01EB28severe
KetoconazoleH02CA03severe

27 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Riociguat in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All riociguat products

Authorised across Europe · EMA

The same active substance is authorised in 9 EEA countries. Names it is sold under:

Austria · Pahrilan
Cyprus · Ridecia
Finland · Midive, Riociguat
Greece · Ridecia, Riociguat Win Medica
Iceland · Adempas
Liechtenstein · Adempas
Malta · Midive, Riociguat
Norway · Adempas
Sweden · Pahrilan, Ridecia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/ee3a4407-df27-46be-ac7b-4d99fd1d3758
GET /v1/drugs/ee3a4407-df27-46be-ac7b-4d99fd1d3758?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h134321_smpc.pdf",
  "strength": null,
  "atc_label": "Riociguat",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg134321",
  "excipients": [
    "CALCIUMCARBONAAT (E 170)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSPOVIDON (E 1202)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "LACTOSE 1-WATER",
    "MACROGOL 400",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMLAURILSULFAAT"
  ],
  "substances": [
    "RIOCIGUAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h134321.pdf",
  "authorised_at": "2026/06/09",
  "procedure_number": "SE/H/2695/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "134321",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about riociguat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console